Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J. Gen. Virol. 2003;84(Pt 2):361-8
Scientific Publications
- PMID: 12560568
- Title: Construction and immunogenicity in a prime boost regimen of a Semliki Forest virus vectored experimental HIV clade A vaccine
- Abstract: A novel, experimental subunit human immunodeficiency virus (HIV) vaccine, SFV.HIVA, was constructed. This consists of Semliki Forest virus (SFV), which is a suitable vaccine vector for use in humans, and a passenger gene encoding HIVA, which is an immunogen derived from HIV-1 clade A that is being currently tested in clinical trials of combined DNA- and modified vaccinia virus Ankara (MVA)-vectored vaccines in Oxford (UK) and Nairobi (Kenya). In the mouse, the SFV.HIVA vaccine was highly immunogenic for T cell-mediated immune responses and induced T cell memory that lasted for at least 6 months. SFV.HIVA was also compared to the vaccines currently used in the clinical trials and was shown to be as effective in T cell induction as pTHr.HIVA DNA but less immunogenic than MVA.HIVA. When tested in a prime-boost regimen, SFV.HIVA-induced responses could be boosted by MVA.HIVA. This work is a part of a long-term effort to build a panel of subunit vaccines expressing a common immunogen, which will allow both a direct comparison of various vaccine vectors and combined vaccination regimens in humans and provide more flexibility and/or a potential optimization of vaccinations for individuals based on their pre-existing anti-vector immunity.
- Date: 1970-08-19
- Year: 2003
- Journal: J. Gen. Virol.
- PMID Author: Hanke T, Barnfield C, Wee EG, Agren L, Samuel RV, Larke N, Liljeström P
- IAVI Topics: HIV Immunogen Design
Construction and immunogenicity in a prime boost regimen of a Semliki Forest virus vectored experimental HIV clade A vaccine
Media Contacts
North America
Rose Catlos
+1 212 847 1049
RCatlos@iavi.org
